- Home
- NMIH vs NRIX Comparison
NMIH vs NRIX Comparison
Compare NMIH & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMIH | NRIX |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.5B |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NMIH | NRIX |
|---|---|---|
| Price | $44.67 | $24.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $43.25 | $30.50 |
| AVG Volume (30 Days) | 451.6K | ★ 1.1M |
| Earning Date | 04-30-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.06 | N/A |
| EPS | ★ 2.66 | N/A |
| Revenue | ★ $706,440,000.00 | $76,987,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.34 | $48.05 |
| P/E Ratio | $16.76 | ★ N/A |
| Revenue Growth | 8.52 | ★ 99.31 |
| 52 Week Low | $34.84 | $8.20 |
| 52 Week High | $46.74 | $25.09 |
Technical Indicators
Market Signals| Indicator | NMIH | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout NMIH NMI Holdings Inc.
NMI Holdings Inc through its subsidiaries provides private mortgage guaranty insurance. The company offers mortgage insurance, reinsurance on loans, and outsourced loan review services to mortgage loan originators. It serves national and regional mortgage banks, money center banks, credit unions, community banks, builder-owned mortgage lenders, Internet-sourced lenders, and other non-bank lenders. It protects lenders and investors from default-related losses on a portion of the unpaid principal balance of a covered mortgage.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.